Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Swiss pharma giant Roche today reported mixed results from late-stage trials for its experimental drug astegolimab, which is ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksTh ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Roche AG’s Genentech unit disclosed outcomes of two studies testing IL-33-targeting astegolimab vs. placebo on top of standard-of-care maintenance therapy in subjects with moderate to very severe ...

Roche announces positive results from pivotal phase IIb ALIENTO & phase III ARNASA trials of astegolimab to treat COPD: Basel Tuesday, July 22, 2025, 13:00 Hrs [IST] Roche announc ...